HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AmStem optimistic about study results

This article was originally published in The Rose Sheet

Executive Summary

San Francisco-based firm - whose Korean facility houses one of the largest banks in the world for umbilical-cord-derived stem cells - announces positive early results from a preliminary consumer study of its SteMixx face cream. More than 64% of responding participants from 21-woman study have made positive comments about the product, says AmStem, which will release full results at the end of the month. Based on initial feedback, "AmStem has engaged a labeling consultant ... to make [SteMixx] available for retail consumer use as soon as possible in the U.S." Firm also says it has finalized its submission to an institutional review board to begin first clinical trial of SteMixx in the U.S. (1"The Rose Sheet" June 21, 2010, Marketing In Brief). SteMixx employs Human Stem Cell Conditioned Media, created during culture of umbilical cord stem cells, to stimulate user's own inherent skin cells and promote skin rejuvenation
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

RS017061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel